Lasa Supergenerics collaborates with ICT for development of antiviral compound Favipiravir as Covid19 Treatment
Favipiravir is an antiviral drug and is a promising antidote for the treatment of Coronavirus disease (COVID-2019). It possesses activity against many RNA viruses. It is a guanine analogue approved for influenza treatment. It can effectively inhibit the RNA-dependent RNA polymerase of RNA viruses such as influenza, Ebola, yellow fever, chikungunya, norovirus and enterovirus, and a recent study reported its activity against 2019-nCoV.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content